<bill session="116" type="s" number="1662" updated="2022-11-01T06:02:36Z">
  <state datetime="2019-05-23">REFERRED</state>
  <status>
    <introduced datetime="2019-05-23"/>
  </status>
  <introduced datetime="2019-05-23"/>
  <titles>
    <title type="display">Opioid Treatment Surge Act</title>
    <title type="short" as="introduced">Opioid Treatment Surge Act</title>
    <title type="official" as="introduced">A bill to establish an annual fee applicable to opioid manufacturers.</title>
  </titles>
  <sponsor bioguide_id="M001176"/>
  <cosponsors/>
  <actions>
    <action datetime="2019-05-23">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-05-23" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="3105" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Health care coverage and access"/>
    <term name="Prescription drugs"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary date="2019-09-24T21:06:40Z" status="Introduced in Senate">Opioid Treatment Surge ActThis bill requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program.</summary>
</bill>
